Ibrutinib, obinutuzumab, idelalisib, and beyond: Review of novel and evolving therapies for chronic lymphocytic leukemia

Pharmacotherapy

Volumn 34, Issue 12, 2014, Pages 1298-1316

  Chung, Clement ^a   Lee, Rosetta ^b  

^a Lyndon B Johnson General Hospital   (United States)

^b HARRIS COUNTY HOSPITAL DISTRICT   (United States)

Author keywords

B cell receptor; bruton tyrosine kinase; CD20; chemoimmunotherapy; chronic lymphocytic leukemia; ibrutinib; idelalisib; microenvironment; obinutuzumab

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE; CHLORAMBUCIL; DINACICLIB; IBRUTINIB; IDELALISIB; ISOSORBIDE; OBATOCLAX; OBINUTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PLERIXAFOR; RITUXIMAB; ULOCUPLUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PURINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINONE DERIVATIVE;

ANEMIA; ARTHRALGIA; BRAIN HEMORRHAGE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); CONTUSION; COUGHING; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; ENZYME INHIBITION; FATIGUE; FEBRILE NEUTROPENIA; FETUS WEIGHT; FEVER; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; INFUSION RELATED REACTION; LEUKOPENIA; LYMPHOCYTOSIS; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEONATAL WEIGHT LOSS; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PNEUMONIA; PROGRESSION FREE SURVIVAL; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIGNAL TRANSDUCTION; STEADY STATE; THROMBOCYTOPENIA; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PURINES; PYRAZOLES; PYRIMIDINES; QUINAZOLINONES;

EID: 84919774523     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1509     Document Type: Review

References (79)

1. Chiorazzi N, Rai KR, Ferrarini M,. Chronic lymphocytic leukemia. New Eng J Med 2005; 352: 804-15.
2. American Cancer Society. Cancer facts and figures. 2014. Available from http://www.cancer.gov/cancertopics/types/melanoma. Accessed 2014 April 17, 2014.
3. Rozovski U, Hazan-Halevy I, Keating M, Estrov Z,. Personalized medicine in CLL: current status and future perspectives. Cancer Lett 2014; 352: 4-14.
4. Herishanu Y, Perez-Galan P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappa B activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011; 117: 563-74.
5. Ghia P, Chiorazzi N, Stamatopoulos K,. Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J Intern Med 2008; 264: 549-62.
6. Buchner M, Baer C, Prinz G, et al. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood 2010; 115: 4497-506.
7. Burger JA, Peled A,. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009; 23: 43-52.
8. Gluzman DF,. WHO classification of lymphoid malignancies. Exp Oncol 2012; 34: 377-8.
9. Tobin G, Thunberg U, Johnson A, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002; 99: 2262-4.
10. Rassenti LZ, Jain S, Keating MJ, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008; 112: 1923-30.
11. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Eng J Med 2004; 351: 893-901.
12. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Eng J Med 2000; 343: 1910-6.
13. Oscier DG, Rose-Zerilli MJ, Winkelmann N, et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 2013; 121: 468-75.
14. Rossi D, Rasi S, Fabbri G, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012; 119: 521-9.
15. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: Non-Hodgkin's lymphomas. V.2.2014. Available from http://www.nccn.org. Accessed April 17, 2014.
16. Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M,. Chronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 6: vi50-4.
17. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112: 975-80.
18. Zenz T, Krober A, Scherer K, et al. Monoallelic TP 53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008; 112: 3322-9.
19. Rossi D, Fangazio M, Rasi S, et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 2012; 119: 2854-62.
20. Pleyer L, Egle A, Hartmann N, Greil R,. Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol 2009; 6: 405-18.
21. Niiro H, Clark EA,. Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2002; 2: 945-56.
22. Fuentes-Panana EM, Bannish G, Monroe JG,. Basal B-cell receptor signaling in B lymphocytes: mechanisms of regulation and role in positive selection, differentiation, and peripheral survival. Immunol Rev 2003; 21: 841-94.
23. Stevenson FK, Caligaris-Cappio F,. Chronic lymphocytic leukemia. Revelations from the B-cell receptor. Blood 2004; 103: 4389-95.
24. Kuppers R,. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005; 5: 251-62.
25. Lenz G, Staudt LM,. Aggressive lymphomas. N Eng J Med 2010; 362: 1417-29.
26. Buggy JJ, Elias L,. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol 2012; 31: 119-32.
27. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010; 107: 13075-80.
28. de Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012; 119: 2590-4.
29. Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012; 119: 1182-9.
30. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011; 117: 6287-96.
31. Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013; 122: 2539-49.
32. Wiestner A,. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood 2012; 120: 4684-91.
33. Pharmacyclics. Imbruvica (ibrutinib) [package insert]. Sunnyvale, CA; 2014.
34. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2012; 31: 88-94.
35. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Eng J Med 2013; 369: 32-42.
36. O'Brien S, Furman RR, Coutre S, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicenter, phase 1b/2 trial. Lancet Oncol 2014; 15: 48-58.
37. O'Brien S, Blum KA, Furman RR, et al. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): follow-up of a phase Ib/II study. [Abstract] Blood Rev. 2011; 118:Abstract # 983.
38. Liu J, Fitzgerald ME, Berndt MC, Jackson CW, Gartner TK,. Bruton's tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo. Blood 2006; 108: 2596-603.
39. Rossi D, Gaidano G,. Richter syndrome: molecular insights and clinical perspectives. Hematol Oncol 2009; 27: 1-10.
40. ™-2). Available from http://clinicaltrials.gov/ct2/show/NCT01722487?term=NCT01722487&rank=1. Accessed April 25, 2014.
41. Brown JR, Barrientos J, Flinn I, et al. The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib combined with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL, interim results of a phase Ib/II study. [Abstract] Haematologica 2012; 97 (): 218 (Abstract # 0543).
42. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibody with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004; 104: 1793-800.
43. Ivanov A, Beers SA, Walshe CA, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009; 119: 2143-59.
44. Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115: 4393-402.
45. Bologna L, Gotti E, Manganini M, et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011; 186: 3762-9.
46. Golay J, Da Roit F, Bologna L, et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood 2013; 122: 3482-91.
47. Morschhauser FA, Cartron G, Thieblemont C, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Onc 2013; 31: 2912-9.
48. Radford J, Davies A, Cartron G, et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood 2013; 122: 1137-43.
49. Genentech. Obinutuzumab (Gazvya) [package insert]. South San Francisco, CA; 2013.
50. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. New Eng J Med 2014; 370: 1101-10.
51. Morschhauser F, Salles G, Cartron G, et al. Dose selection for phase III studies of the monoclonal anti-CD20 antibody obinutuzumab (GA101)-a rational approach. [Abstract] Haematologica 2011; 96 (Suppl 2): 935.
52. Bauer K, Rancea M, Roloff V, et al. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukemia. Cochrane Database Syst Rev 2012; 11: CD008079. doi: 10.1002/14651858.CD008079.pub2.
53. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: a randomized, open-label, phase 3 trial. Lancet 2010; 376: 1164-74.
54. Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001; 98: 1326-31.
55. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 1749-55.
56. Byrd JC, Brown JR, O'Brien S,. Ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia. N Eng J Med 2014; 371: 213-23.
57. Raphael B, Anderson JW, Silber R, et al. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology group randomized clinical trial. J Clin Oncol 1991; 9: 770-6.
58. ClinicalTrials.gov. A Safety Study of obinutuzumab alone or in combination with chemotherapy in patients with chronic lymphocytic leukemia. Available from http://clinicaltrials.gov/ct2/show/NCT01905943?term=obinutuzumab&rank=10. Accessed July 4, 2014.
59. Okkenhaug K, Vanhaesebroeck B,. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol 2003; 3: 317-30.
60. Srinivasan L, Sasaki Y, Calado DP, et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 2009; 139: 573-86.
61. Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010; 116: 2078-88.
62. Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011; 117: 591-4.
63. Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011; 118: 3603-12.
64. Brown R, Furman RR, Flinn I, et al. Final results of a phase I study of idelalisib (GSE 1101) a selective inhibitor of PI3K {delta}, in patients with relapsed or refractory CLL. [Abstract]. J Clin Oncol 2013; Abstract # 7003.
65. Barrientos JC, Furmann RR, Leonard J, et al. Update on a phase I study of the selective PI3K {delta} inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL [Abstract]. J Clin Oncol 2013; 31: Abstract # 7017.
66. O'Brien SM, Lamanna N, Kipps TJ, et al. A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3K {delta}) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naïve patients (pts) > = 65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [Abstract]. J Clin Oncol 2013; 31: Abstract # 7005.
67. Gilbert JA,. Idelalisib: targeting PI3Kδ in B-cell malignancies. Lancet Oncol 2014; 15: e108.
68. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3 kinase p110, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014; 123: 3390-7. doi: 10.1182/blood-2013-11-535047.
69. Kahl BS, Spurgeon SE, Furman RR, et al. Results of a phase I study of idelalisib, a PI3Kδinhibitor, in patients with relapsed or refractory mantle cell lymphoma (MCL). Blood 2014; 123: 3398-405. doi: 10.1182/blood-2013-11-537555.
70. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370: 997-1007.
71. Cosimo E, Mccaig AM, Carter-Brzezinski LJ, et al. Inhibition of NF- κB mediated signaling by the CDK inhibitor CR8 overcomes apoptosis in chronic lymphocytic leukemia cells. Clin Cancer Res 2013; 19: 2393-405.
72. Parry D, Guzi T, Shanahan F, et al. Dinaciclib (SCH727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 2010; 9: 2344-53.
73. Johnson AJ, Yeh YY, Smith LL, et al. The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells. Leukemia 2012; 26: 2554-7.
74. Flinn JM, Jones JA, Andritsos L, et al. Phase I study of the CDK inhibitor dinaciclib (SCH727965) in patients with relapsed/refractory CLL. [Abstract] J Clin Oncol 2011; Abstract # 6623.
75. Herishanu Y, Gibellini F, Njuguna N, et al. Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1. Leuk Lymphoma 2011; 52: 1758-69.
76. Hendrix CW, Flexner C, MacFarland RT, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000; 44: 1667-73.
77. Uy GL, Rettig MP, Motabi IH, et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012; 119: 3917-24.
78. O'Brien SM, Claxton DF, Crump M, et al. Phase I study of obatociax mesylate (GX15-070), a small molecule pan-BCl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2008; 113: 299-305.
79. Balekrishnan K, Burger JA, Wierda WG, et al. AT-101 induces apoptosis in CLL B-cells and overcomes stromal cell-mediated MCl-1 induction and drug resistance. Blood 2008; 113: 149-53.